A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis

Trial Profile

A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

At a glance

  • Drugs Ceftobiprole (Primary) ; Aztreonam; Daptomycin
  • Indications Bacteraemia; Staphylococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Basilea Pharmaceutica
  • Most Recent Events

    • 29 Apr 2017 Status changed from planning to not yet recruiting.
    • 20 Feb 2017 According to a Basilea Pharmaceutica media release, this trial will be conducted under a Special Protocol Assessment and results from this trial may support a potential regulatory filing in the US for the approval of ceftobiprole. This trial is one of the 2 studies in the phase III program of ceftobiprole.
    • 20 Feb 2017 This trial is expected to begin in mid-2017, according to a Basilea Pharmaceutica media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top